Who
Isaac Manke
Director
Company insider
Files Form 4 as: Director, Addex Therapeutics; Director, OnKure Therapeutics; Director, Q32 Bio.
In numbers
- Trades disclosed
- 39
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 25 Mar 2024
- Last trade
- 2 Sep 2026
- Last filed
- 4 Sep 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex TherapeuticsBiotechnology | SEC FORM 4 Code D | —219,561 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex TherapeuticsBiotechnology | SEC FORM 4 Code A | —219,561 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex TherapeuticsBiotechnology | SEC FORM 4 Code D | —219,561 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex TherapeuticsBiotechnology | SEC FORM 4 Code A | —219,561 at $0.00 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —15,300 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,300 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —15,300 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,300 | filing |
| 30 Jun 2026filed 2 Jul 2026 | QTTB Q32 BioBiotechnology | SEC FORM 4 Code M | $150K53,521 at $2.80 | filing |
| 30 Jun 2026filed 2 Jul 2026 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —53,521 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —53,521 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | QTTB Q32 BioBiotechnology | SEC FORM 4 Code M | $150K53,521 at $2.80 | filing |
| 12 Jun 2026filed 21 Jul 2026 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,826 at $0.00 | filing |
| 12 Jun 2026filed 21 Jul 2026 | QTTB Q32 Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,826 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.